Hologic CE marks Adiana contraceptive
This article was originally published in Clinica
Executive Summary
Hologic has CE marked its radiofrequency-based Adiana permanent contraception system for sale in Europe. The transcervical Adiana procedure uses a bi-polar radiofrequency energy catheter to remove cells lining a 1cm section of the inside of the fallopian tube. The catheter then delivers a soft polymer implant into the prepared section of the tube. The procedure is repeated on the other tube. The procedure is designed such that healthy tissue will grow into the matrix to create a complete blockage of each tube. The device is awaiting approval in the US, Canada and Australia, Bedford, Massachusetts-based Hologic said.
You may also be interested in...
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.